Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 6123360

Decrease in gamma-glutamyl transpeptidase activity in early amniotic fluid in fetal trisomy 18 syndrome.

H Janlanko·P Aula
View original source ↗Export metadata ↓

Abstract

A study was carried out in which activity of gamma-glutamyl transpeptidase was measured in 259 samples of amniotic fluid obtained at various weeks of pregnancy. Two hundred and twenty-eight of the babies subsequently delivered had no chromosome abnormality and served as controls, while in 31 various chromosome abnormalities were detected. Mean activity of gamma-glutamyl transpeptidase in the control samples at 15 weeks was 602 U/l. Activity in the samples obtained in cases of fetal chromosome abnormality was generally below this: it was below the 10th percentile in 74% of the samples and below the 2.5th percentile in 52% of the cases. It is concluded that assay of gamma-glutamyl transpeptidase activity is a rapid preliminary test for prenatal diagnosis of chromosomal abnormalities.

Explore related subjects

Amniotic FluidChromosome AberrationsChromosome DisordersChromosomes, Human, 16-18FemaleHumansPregnancyPrenatal DiagnosisTrisomygamma-GlutamyltransferaseJournal ArticleResearch Support, Non-U.S. Gov't

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

H Janlanko, P Aula. 1982-05-29. Decrease in gamma-glutamyl transpeptidase activity in early amniotic fluid in fetal trisomy 18 syndrome.. https://doi.org/10.1136/bmj.284.6329.1593

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed2007

Perinatal outcomes of pregnancies with borderline amniotic fluid index.

OBJECTIVE: Our aim was to determine whether a borderline amniotic fluid index observed during antepartum testing confers a significant risk of adverse perinatal outcome. METHODS: Between April 2001 and May 2005, uncomplicated gestations with a singleton non-anomalous fetus, who underwent weekly monitoring of amniotic fluid index (AFI) until delivery during the last trimester and who gave birth at our hospital, were identified for our study. Normal amniotic fluid volume and borderline amniotic fluid were defined as AFI of >10 and <24 cm and >5 and <10 cm, respectively. The groups were compared on maternal data, mode of delivery and perinatal outcomes such as fetal distress, intrauterine growth restriction and meconium fluid. RESULTS: A total of 90 cases were identified as borderline amniotic fluid and 277 cases as normal AFI. We observed significant increased incidences of admission to neonatal intensive care unit, intrauterine growth restriction, meconium-stained amniotic fluid, intrapartum fetal distress in the group with borderline amniotic index (P < 0.05). CONCLUSIONS: A borderline amniotic fluid index observed in antepartum testing during the last trimester carries an increased risk of adverse perinatal outcomes. These patients should be followed up carefully during the antepartum and intrapartum period.

Amniotic Fluid↗
PubMed2007

Isolation of amniotic stem cell lines with potential for therapy.

Stem cells capable of differentiating to multiple lineages may be valuable for therapy. We report the isolation of human and rodent amniotic fluid-derived stem (AFS) cells that express embryonic and adult stem cell markers. Undifferentiated AFS cells expand extensively without feeders, double in 36 h and are not tumorigenic. Lines maintained for over 250 population doublings retained long telomeres and a normal karyotype. AFS cells are broadly multipotent. Clonal human lines verified by retroviral marking were induced to differentiate into cell types representing each embryonic germ layer, including cells of adipogenic, osteogenic, myogenic, endothelial, neuronal and hepatic lineages. Examples of differentiated cells derived from human AFS cells and displaying specialized functions include neuronal lineage cells secreting the neurotransmitter L-glutamate or expressing G-protein-gated inwardly rectifying potassium channels, hepatic lineage cells producing urea, and osteogenic lineage cells forming tissue-engineered bone.

Amniotic Fluid↗